Kyowa Kirin Co.,Ltd. Logo

Kyowa Kirin Co.,Ltd.

Develops antibody medicines for oncology, nephrology, immunology, and allergy.

4151 | T

Overview

Corporate Details

ISIN(s):
JP3256000005
LEI:
Country:
Japan
Address:
千代田区大手町一丁目9番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyowa Kirin is a global specialty pharmaceutical company dedicated to addressing unmet medical needs through innovative drug discovery. The company engages in the research, development, manufacturing, and commercialization of pharmaceuticals and biotechnology products. Focusing on core therapeutic areas such as nephrology, oncology, immunology, and allergy, Kyowa Kirin leverages its advanced antibody technologies to create novel medicines. Guided by its mission of "Commitment to Life," the organization strives to deliver life-changing value to patients, their families, and medical professionals worldwide by developing and marketing innovative prescription drugs that contribute to global health and well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:30
Interim Report
半期報告書-第103期(2025/01/01-2025/12/31)
Japanese 991.7 KB
2025-07-31 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-07-11 09:30
Regulatory News Service
臨時報告書
Japanese 21.2 KB
2025-03-21 06:47
Registration Form
訂正有価証券届出書(参照方式)
Japanese 46.5 KB
2025-03-21 06:41
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB
2025-03-19 07:51
Registration Form
有価証券届出書(参照方式)
Japanese 56.3 KB
2025-03-11 07:31
Annual Report
有価証券報告書-第102期(2024/01/01-2024/12/31)
Japanese 4.0 MB
2025-03-11 07:31
Governance Information
内部統制報告書-第102期(2024/01/01-2024/12/31)
Japanese 22.5 KB
2025-03-11 07:31
Registration Form
確認書
Japanese 8.2 KB
2024-11-14 07:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.6 KB
2024-10-31 07:30
Board/Management Information
臨時報告書
Japanese 26.1 KB
2024-10-11 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-09-12 08:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2024-08-09 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.1 KB
2024-08-01 08:31
Interim Report
半期報告書-第102期(2024/01/01-2024/12/31)
Japanese 916.7 KB

Automate Your Workflow. Get a real-time feed of all Kyowa Kirin Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kyowa Kirin Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kyowa Kirin Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.